MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
EXEL — Exelixis Inc
NasdaqExelixis Inc
$58.39
+0.45(+0.78%)
- O
- 58.11
- H
- 58.97
- L
- 57.94
- V
- 1.95M
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About EXEL
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateApr 11, 2000
Employees1,077
Stock ExchangeNasdaq
Ticker SymbolEXEL
Websitehttps://www.exelixis.com
Key Financial Statistics
| Market Cap | $14.47B |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $33.76 - $61.14 |
| 52-Week Avg Volume | 2.64M |
| VWAP | $58.44 |
| Transactions | 27,035 |
| Total Recorded Bars | 6,654 days |